U.S. senators call for update of national cancer access act

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 4
Volume 18
Issue 4

Sen. Edward Kennedy (D-Mass.) and Sen. Kay Bailey Hutchison (R-Tex.) introduced the 21st Century Cancer Access to Life-saving Early detection, Research and Treatment Act. The goal of the ALERT Act is to modernize and advance the national cancer program in the U.S.

Sen. Edward Kennedy (D-Mass.) and Sen. Kay Bailey Hutchison (R-Tex.) introduced the 21st Century Cancer Access to Life-saving Early detection, Research and Treatment Act. The goal of the ALERT Act is to modernize and advance the national cancer program in the U.S.

The ALERT Act will provide funding for promising research in early detection, supply grants for screening, and make referrals for treatment. The bill is an update on the National Cancer Act of 1971 and is intended to bring a renewed focus on research and prevention.

The senators asked key stakeholders, such as the American Association for Cancer Research (AACR), for input in identifying challenges in cancer research and to help craft legislation to present solutions for the pandemic.

The ALERT Act represents a critical step in modernizing the national cancer program, said Margaret Foti, PhD, MD, chief executive officer of AACR.

 

Recent Videos
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video